Navigation Links
Treatment over a longer period for blood clotting

Venous thromboembolism is a condition which causes clotting in the veins. Typical therapy for venous thromboembolism includes a five- to 10-day course of heparin followed by three to 12 months of the oral drug warfarin. However, the problem with this treatment is that once the patient goes off warfarin, venous thromboembolism recurs. While recurrence rates of this problem are reduced if the patient stays on warfarin, according to previous studies, it// also puts the patient at an increased risk for a major hemorrhage. Researchers have now conducted a study to find out whether keeping patients on a low-dose of warfarin would be beneficial or too much of a risk.

The study included more than 500 patients who received standard treatment and then were assigned to receive a placebo or low-intensity warfarin. Participants were followed to see who had recurrent venous thromboembolism, major hemorrhage, and who died. After four years, researchers found that 37 of the 253 patients assigned to the placebo had recurrent venous thromboembolism, as compared with 14 of the 255 patients on the low-intensity warfarin. This indicated a risk reduction of 64 percent. Furthermore, major hemorrhage occurred in two patients on the placebo and five on the warfarin. Researchers claimed that the reduction in the risk of recurrent venous thromboembolism for patients on low-intensity warfarin, after adjusting for other factors, was between 76 percent and 81 percent.

Andrew Schafer, M.D., from the University of Pennsylvania School of Medicine, in an accompanying editorial said that though researchers claim short-term treatment reduces the risk of recurrent venous thromboembolism by up to 81 percent, doctors are continuing to walk a tightrope for dosing medicine for patients with venous thromboembolism. Although low-intensity warfarin may prevent recurrent venous thromboembolism it is unclear what dosage doctors need to give to prevent recurrence and not cause major bleedin g.


'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2017)... ... May 26, 2017 , ... The American ... review more than eighty-nine grant submissions all vying for nearly $1,000,000 in funding ... Parkinson’s field.     , The American Parkinson Disease Association (APDA) is focused on advancing ...
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, a leading provider of ... with its Somnoware Sleep Device Interface (SDI). Somnoware SDI is a sleep device ... this platform, initializing devices and importing studies are just one-click operations. This plugin ...
(Date:5/26/2017)... ... 2017 , ... On May 24, the Congressional Budget Office (CBO) projected that ... May 4, would result in 23 million Americans losing their health insurance by 2026 ... Protection and Affordable Care Act (ACA). , “It is clear from the CBO ...
(Date:5/26/2017)... , ... May 26, 2017 , ... Rob Lowe acts ... upcoming production of the series is on hiking in American. Viewers can reconnect with ... the great benefits of hiking. , Many consumers have looked for an inventive new ...
(Date:5/26/2017)... ... May 26, 2017 , ... Centennial-based ... of proceeds from its 14th Annual Clays for Kids fundraiser, to be held ... Bennett, Colorado. , As part of BluSky’s partnership with The Adoption Exchange, ...
Breaking Medicine News(10 mins):
(Date:5/24/2017)... Va. , May 24, 2017  ivWatch ... Original Equipment Manufacturer (OEM) Board to enable seamless ... with patient monitoring systems, infusion pumps and other ... OEMs will be able to help health care ... and reduced risks related to IV therapy. ...
(Date:5/22/2017)... May 22, 2017  Lilac Corp, the company ... the launch of a new website . ... of a clinical study that showed surprising clearance ... Gene-Eden-VIR/Novirin in individuals suffering from HPV warts, precancerous, ... there are no other treatments that clear the ...
(Date:5/18/2017)... WHIPPANY, N.J. , May 18, 2017  Two ... Healthcare Businesswomen,s Association (HBA) during its recent 28 th ... New York City.  The event showcases HBA,s longstanding mission ... the business of healthcare. Cindy Powell-Steffen ... in Bayer,s U.S. Radiology division, and Libby Howe ...
Breaking Medicine Technology: